Furthermore, upon the thorough insight into pan-cancer models, Cioffi, M., et al. found that miR-93 and miR-106b diminished tumor immunity and metastasis of cancer cells respectively by targeting the programmed death ligand 1 (PD-L1) which is known as the immune checkpoint inhibitors that could inhibit immune response [128], and downregulating the production of the chemoattractant CXCL12 [129], uncovering the strong immunosuppressive and metastatic phenotypes built by ncRNA. Here, CXCL12 is linked to cancer.